AzTrials
AzTrials

Post-acne ErythemaPhase 2NCT07884565

Comparison of Fractional CO2 Laser Monotherapy and Its Combination With Either Topical Vitamin C or Topical Timolol in the Treatment of Post-Acne Erythema: A Split Face Study

A Phase 2 study testing topical Timolol maleate 0.5% eye drops, topical Vitamin C 15% and Fractional CO2 laser in people with Post-acne Erythema, run by Cairo University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Acne is very common, especially among young adults. After acne heals, some people are left with persistent red or pink marks, called post-acne erythema (PAE). These marks can last for several months and, in some people, may be associated with a higher risk of developing acne scars. Read more about this study

Who is it for?
Ages 15 years and olderHealthy volunteers can take part
Conditions the study is for
Post-acne Erythema
What is being tested?
topical Timolol maleate 0.5% eye drops, topical Vitamin C 15% and Fractional CO2 laser
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteEgypt
Study dates
30 Aug 2023to 30 Jul 2025
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 15 years and older
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • Patients 15 years old or more with persistent postacne erythema for >= 1month
  • Both gender with post acne erythema

Who cannot join

  • Pregnant or lactating female patients.
  • Other local cutaneous skin disorder or infections e.g. HSV
  • Concurrent isotretinoin treatment , or within the last three months.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Kasr Alainy, Cairo University

    Cairo, Cairo Governorate, 11562

Other trials in Egypt

About this study

Acne is very common, especially among young adults. After acne heals, some people are left with persistent red or pink marks, called post-acne erythema (PAE). These marks can last for several months and, in some people, may be associated with a higher risk of developing acne scars.

PAE is more common in people with lighter skin. It is thought to happen because healing after acne can cause changes in the small blood vessels in the skin, making them wider and more visible. Skin irritation from some acne treatments may also contribute to the redness.

Read more

There is currently no single treatment that is considered the best treatment for post-acne redness. Several treatments have shown benefits, including different types of lasers and light treatments, as well as topical creams or serums such as vitamin C, tranexamic acid, oxymetazoline, and brimonidine. Timolol, a medication that can narrow small blood vessels, has also recently shown promising results.

Fractional CO₂ laser may help improve post-acne redness by stimulating skin healing and affecting the small blood vessels responsible for the redness. Other fractional lasers have also been shown to improve PAE.

Vitamin C is a powerful antioxidant that can help protect and repair the skin. When applied directly to the skin, it may reduce inflammation, support collagen production, and promote healing. Studies have shown improvement in post-acne redness with topical vitamin C.

Timolol is a medication that can cause narrowing of small blood vessels and may reduce the formation of new blood vessels. Because of these effects, it has recently been studied as a treatment for post-acne redness.

Because there is still no established standard treatment for PAE, this study was designed to compare three approaches: fractional CO₂ laser alone, fractional CO₂ laser combined with vitamin C, and fractional CO₂ laser combined with timolol. The goal is to determine which approach provides the best improvement in post-acne redness.

Read the detailed description

Background:

Acne vulgaris is one of the most prevalent causes of the clinic visit among young adults. Post-acne erythema (PAE) is one of the major sequelae of acne vulgaris and it commonly persists for long times as several months. It can be a predictor of developing atrophic scars in predisposed people. It almost develops in individuals with light skin phototypes. Although the exact mechanism of PAE is unknown, it is thought to occur secondary to epidermal thinning with resultant telengectasia and dermal vascular dilatation changes in response to the healing process. Other explanation is that PAE results from external agents as topical therapy which may cause irritation. Searching the literature, different results were found yet no gold standard treatment for PAE could be found till now. A very novel review categorized treatment of PAE into light and laser therapies which included; alexanderite (Alex) laser, pro-yellow laser, erbium glass fractional laser, Q-switched Neodymium:yttrium aluminum-garnet (Nd:YAG) laser pulsed dye laser, high power optically pumped semiconductor laser (HOPSL), broad band treatment, intense pulsed light (IPL) therapy, and radiofrequency (both fractional microneedling, and invasive short pulsed-type bipolar radiofrequency device (IPBRF)), they were all found to be effective modalities. The other modalities mentioned with also favorable outcome and more affordability were topical therapies including; 1.5% Oxymetazoline (OXZ), 5% tranexamic acid, vitamin C gel, brimonidine tartarate 0.2%, and a topical complex containing Glyceryl-octyl-ascorbic acid (GOVC), ascorbyl 2-phosphate 6-palmitate (APP), and DL-a- tocopherol phosphate (TP). Moreover topical timolol was found recently to be an effective option for PAE treatment. Fractional Co2 laser role in post acne erythema scars wasn't found in the literature; yet a study by Park et al, illustrated the role of fractional potothermolysis of 1550 nm, erbium-doped laser in PAE by many theories including; targeting tissue water which is a major component of blood vessels, it also results in photothermal damage of dermal vasculature leading to improved erythema. In addition, it produces multitudes of dermal microthermal zones of injury that may lead to multiple, random targeting of the dermal blood vessels. Although pulsed dye laser (PDL) targets hemoglobin, the fact that fractional laser penetrates deeper adds a more benefit for the more deeply located vessels in the dermis. Vitamin C (Vit. C) is a known potent antioxidant. A limited amount of vit. C is absorbed regardless the oral dose, due to its active transport. Moreover, vit. C bioavailability in the skin is insufficient with its oral intake, so its topical preparations are preferred in dermatological uses. It is used in numerous dermatological purposes including; photodamage, hyperpigmentation, and rejuvenation. A Japanese study was done using Isostearyl-L-ascorbic acid (ISAA) for treatment of post acne erythema, and post inflammatory hyperpigmentation and found significant improvement. They attributed this role to wound healing promoting effects of vitamin C through proliferation of collagen synthesis and inhibition of matrix metalloproteinase (MMP), and inhibition of tyrosinase. Besides, Vitamin C has anti-inflammatory effects by inhibiting pro-inflammatory cytokines including; IL1β, and TNF-α. Another study was done combining Vit.C with tranexemic acid and microneedling has found significant decrease in post acne erythema scars in comparison with microneedling alone.

Timolol, is a well tolerated nonselective β-adrenergic receptor blocker, its use becomes obviously increasing nowadays in a lot of dermatological purposes such as; infantile hemangioma, wound healing, Kaposi sarcoma, pyogenic granuloma. Moreover, it was reported recently to be effective in PAE treatment by inducing vasoconstriction, and inhibiting neoangiogenesis, this is deduced from its known role in treatment of infantile hemangioma. Taken together, and to the best of our knowledge, the literature lacks gold standard treatment for post acne erythema management, and no studies were found to compare effects of combined fractional CO2 laser with timolol Vs, fractional Co2 laser combined with Vit. C, Vs, fractional Co2 alone in patients of post acne erythema, which necessitates to be evaluated, to reach a better consensus while dealing with such common sequel.

Objectives:

  • Assessment of efficacy of fractional laser in post acne erythema. - Assessment of topical vitamin C combined with fractional laser in treatment of post acne erythema. - Assessment of topical timolol combined with fractional laser in treatment of post acne erythema. - Comparison between efficacy of fractional Co2 laser combined with topical vitamin C Versus, fractional Co2 laser with topical timolol Versus, fractional Co2 laser alone in patients with post acne erythema.

Study design:

Randomized controlled trial

Study Methods

  • Population of study: Patients with post acne erythema from outpatient dermatology department clinic, Kasr Alainy.
  • Forty (40) Patients -with persistent post acne erythema for one month after acne vulgaris resolution or more- from outpatient dermatology department clinic, Kasr Alainy will be collected and written informed consent will be taken.
  • Twenty patients(20) will undergo a split face study, with half face application of fractional Co2 session with the following parameters( power:15J, Dual time: 700, spacing:500, stack:1) followed by topical Vitamin C, the other half will undergo a fractional Co2 session alone. The other twenty patients (20) will undergo a split face study as well, with half face application of fractional Co2 session with the following parameters( power:15J, Dual time: 700, spacing:500, stack:1) followed by topical timolol 0.5% drops, the other half will undergo a fractional Co2 session alone.
  • Laser sessions will be done every month for three months, and topical treatment will be continued in the intervals between sessions.
  • Evaluation of patients will be done by dermoscopy, spectrophotometry, photography, and clinician erythema assessment scale (CEAS).
  • Randomization will be carried out by asking patients who fulfill the inclusion criteria to draw closed opaque envelopes to determine to which group they will be assigned.
  • Patients will be followed for three months after the treatment duration.

Statistical analysis • The collected data will be coded, entered, presented, and analyzed by computer using a database software program, Statistical Package for Social Science (SPSS) version.

  • Qualitative data will be represented as frequencies and percent and Chi square (X2) test was used to detect relation between different qualitative variables.
  • For quantitative variables mean ± standard deviation (SD) and median with range (for not normally distributed data) will be computed and Independent t-test (t) will be used for detection of difference between different quantitative variables, while nonparametric data will be evaluated with Mann-Whitney U test. funding: Vichy will fund us with topical Vitamin C 15%
Being tested
topical Timolol maleate 0.5% eye drops, topical Vitamin C 15%, Fractional CO2 laser

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • topical Timolol maleate 0.5% eye dropsDrug

    Group B received fractional CO₂ laser plus topical Timolol(after and between laser sessions) on the right side of the face

  • topical Vitamin C 15%Drug

    Group A received fractional CO₂ laser plus topical Vitamin C (after and between laser sessions) on the right side of the face

  • Fractional CO2 laserDevice

    Group C received left-sided application of fractional CO2 laser alone

Study groups in NCT07884565
Study groupRoleWhat they receive
Fractional CO2 aloneActive comparator40 patients enrolled in the study have a left-sided split-face application of fractional CO2 monotherapy
Receives: Device: Fractional CO2 laser
Fractional CO2+Topical Vitamin CActive comparatorTwenty (20) patients have right-sided application of topical vitamin C after and between sessions of fractional CO2 laser
Receives: Drug: topical Vitamin C 15%; Device: Fractional CO2 laser
Fractional CO2 laser + Topical TimololActive comparatorTwenty (20) patients have right-sided application of topical timolol after and between sessions of fractional CO2 laser
Receives: Drug: topical Timolol maleate 0.5% eye drops; Device: Fractional CO2 laser

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The percentage of improvement in post-acne erythema from baseline using erythema assessment scores.

    Assessment made using erythema scores as the clinician erythema assessment scale, and dermoscopy.

    Also, patient satisfaction assessment, and Investigator global assessment were used.

    Measured: 4 months

Secondary outcomes (1)
  1. Reaching a common consensus with post-acne erythema management in future.

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Oct 2026
  2. Study start30 Aug 2023
  3. Primary completion1 Jan 2025
  4. Study completion30 Jul 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
* Forty (40) Patients -with persistent post acne erythema for one month after acne vulgaris resolution or more- from outpatient dermatology department clinic, Kasr Alainy will be collected and written informed consent will be taken. * Twenty patients(20) will undergo a split face study, with half face application of fractional Co2 session with the following parameters( power:15J, Dual time: 700, spacing:500, stack:1) followed by topical Vitamin C, the other half will undergo a fractional Co2 session alone. The other twenty patients (20) will undergo a split face study as well, with half face application of fractional Co2 session with the following parameters( power:15J, Dual time: 700, spacing:500, stack:1) followed by topical timolol 0.5% drops, the other half will undergo a fractional Co2 session alone. * Laser sessions will be done every month for three months, and topical treatment will be continued in the intervals between sessions. * Evaluation of patients
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07884565
Sponsor's protocol ID
md-371-2022
Status last verified
Oct 2026
First submitted
4 Oct 2026
Last updated
20 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes

Publications

  • Amiri R, Khalili M, Mohammadi S, Iranmanesh B, Aflatoonian M. Treatment protocols and efficacy of light and laser treatments in post-acne erythema. J Cosmet Dermatol. 2022 Feb;21(2):648-656. doi: 10.1111/jocd.14729. Epub 2022 Jan 5.

    PubMed 34985175
  • Alzaid M, Al-Naseem A, Al-Niaimi F, Ali FR. Topical timolol in dermatology: infantile haemangiomas and beyond. Clin Exp Dermatol. 2022 May;47(5):819-832. doi: 10.1111/ced.15021. Epub 2022 Jan 13.

    PubMed 34798680
  • Afra TP, Razmi T M, De D. Topical timolol for postacne erythema. J Am Acad Dermatol. 2021 Jun;84(6):e255-e256. doi: 10.1016/j.jaad.2020.04.144. Epub 2020 May 4. No abstract available.

    PubMed 32376427

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing topical Timolol maleate 0.5% eye drops, topical Vitamin C 15% and Fractional CO2 laser in people with Post-acne Erythema, run by Cairo University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The percentage of improvement in post-acne erythema from baseline using erythema assessment scores. (time frame: 4 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07884565, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in